Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Hallucinogen
|
| gptkbp:actsOn |
serotonin receptor agonist
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
520-52-5
|
| gptkbp:category |
alkaloid
psychedelic tryptamine serotonin receptor agonist |
| gptkbp:chemicalFormula |
C12H16N2O
|
| gptkbp:color |
white to off-white
|
| gptkbp:degradedBy |
oxygen
heat light |
| gptkbp:discoveredBy |
gptkb:Albert_Hofmann
|
| gptkbp:discoveredIn |
1958
|
| gptkbp:excretion |
urine
|
| gptkbp:foundIn |
psilocybin mushrooms
|
| gptkbp:halfLife |
1–3 hours
|
| gptkbp:hasInChIKey |
KZPZGVMLZUAESH-UHFFFAOYSA-N
|
| gptkbp:hasSMILES |
CN(C)CCC1=CNC2=CC(=O)C=CC2=C1
|
| https://www.w3.org/2000/01/rdf-schema#label |
Psilocin
|
| gptkbp:IUPACName |
4-hydroxy-N,N-dimethyltryptamine
|
| gptkbp:legal_status_in_UK |
Class A drug
|
| gptkbp:legalStatus |
Schedule I controlled substance
|
| gptkbp:meltingPoint |
173–176 °C
|
| gptkbp:metabolism |
liver
|
| gptkbp:metabolite_of |
psilocybin
|
| gptkbp:molecularWeight |
204.27 g/mol
|
| gptkbp:pharmacological_effect |
mystical experiences
euphoria hallucinations altered perception |
| gptkbp:PubChem_CID |
10624
10186 CHEMBL391 |
| gptkbp:relatedTo |
gptkb:DMT
gptkb:bufotenin psilocybin |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous insufflation |
| gptkbp:solubility |
slightly soluble in water
soluble in ethanol soluble in chloroform soluble in methanol |
| gptkbp:UNII |
4UFN936YRU
|
| gptkbp:bfsParent |
gptkb:Psilocybe_azurescens
|
| gptkbp:bfsLayer |
6
|